Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.63 |
| ▸ | MDM4 | O15151 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29415586 | 1.00 | CASP3 (0.63) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL29423393 | 1.00 | CASP3 (0.63) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL29493550 | 1.00 | CASP3 (0.63) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL2558967 | 1.00 | CASP3 (0.63) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL15480253 | 1.00 | CASP3 (0.63) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL8904188 | 1.00 | CASP3 (0.63) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL16401903 | 1.00 | CASP3 (0.63) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL2558970 | 1.00 | CASP3 (0.63) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL22283176 | 1.00 | CASP3 (0.63) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL23138547 | 0.94 | CASP3 (0.58) | CASP3MDM4TP53KMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220135594-A1 | METHODS OF SYNTHESIS AND INTERMEDIATES | MEDIMMUNE LIMITED (GB) | 2022-05-05 | — | — | US | claimed |
| WO-2026098633-A1 | CONJUGATES AND USES THEREOF | CSTONE PHARMACEUTICALS (SUZHOU) CO., LTD. (CN) | 2026-05-15 | — | — | WO | disclosed |
| US-12589101-B2 | Cyclodextrin protein drug conjugates | REGENERON PHARMACEUTICALS, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-12576158-B2 | Antibody drug conjugates with cleavable linkers | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2026-03-17 | — | — | US | disclosed |
| US-20260021196-A1 | HOMOGENEOUS ANTIBODY-CONJUGATES WITH HIGH PAYLOAD LOADING | SYNAFFIX BV (NL) | 2026-01-22 | — | — | US | disclosed |
| EP-4673474-A2 | ANTI-PSMA ANTIBODIES, CONJUGATES, AND METHODS OF USE | Eisai R&D Management Co., Ltd. (JP) | 2026-01-07 | — | — | EP | disclosed |
| US-12497460-B2 | Anti-MSR1 antibodies and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| EP-4658318-A1 | HOMOGENEOUS ANTIBODY-CONJUGATES WITH HIGH PAYLOAD LOADING | Synaffix B.V. (NL) | 2025-12-10 | — | — | EP | disclosed |
| EP-4659809-A2 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2025-12-10 | — | — | EP | disclosed |
| EP-4622678-A1 | ANTIBODY-DRUG CONJUGATE COMPRISING AN ANTI-GUCY2C ANTIBODY AS WELL AS METHODS OF PRODUCTION AND USES THEREOF | Heidelberg Pharma Research GmbH (DE) | 2025-10-01 | — | — | EP | disclosed |
| US-20220175875-A1 | METHODS OF TREATING CANCER BY TARGETING TUMOR-ASSOCIATED MACROPHAGES | ENDOCYTE INC (US) | 2022-06-09 | — | — | US | disclosed |
| CN-114585636-A | Preparation method of procatide | 深圳市健元医药科技有限公司 | 2022-06-03 | — | — | CN | disclosed |
| CN-108349960-B | Nostoc compounds and conjugates, their preparation and their therapeutic use | 赛诺菲 | 2022-05-27 | — | — | CN | disclosed |
| EP-3423104-B1 | AMANITIN CONJUGATES | HEIDELBERG PHARMA RES GMBH (DE) | 2022-05-18 | — | — | EP | disclosed |
| US-20220135594-A1 | METHODS OF SYNTHESIS AND INTERMEDIATES | MEDIMMUNE LIMITED (GB) | 2022-05-05 | — | — | US | disclosed |
| CN-109790178-B | Novel cytotoxic agents and conjugates thereof | 宝力泰锐克斯有限公司 | 2022-05-03 | — | — | CN | disclosed |
| US-20220112158-A1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDES AND PROTEIN CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2022-04-14 | — | — | US | disclosed |
| EP-3972648-A1 | ANTIBODY DRUG CONJUGATES WITH CLEAVABLE LINKERS | Heidelberg Pharma Research GmbH (DE) | 2022-03-30 | — | — | EP | disclosed |
| US-20220080052-A1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDE DERIVATIVES AND PROTEIN CONJUGATES THEREOF FOR USE AS LXR AGONISTS | REGENERON PHARMACEUTICALS, INC. | 2022-03-17 | — | — | US | disclosed |
| CN-114144201-A | Antibody drug conjugates containing a cleavable linker | 海德堡医药研究有限责任公司 | 2022-03-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021196-A1 | HOMOGENEOUS ANTIBODY-CONJUGATES WITH HIGH PAYLOAD LOADING | FCGR2A, FCGR3B, FCGR1A | CASP3 4757/4885MDM4 3708/4885TP53 1681/4885 |
| US-12589101-B2 | Cyclodextrin protein drug conjugates | SSB, CHP1, IAPP | CASP3 2915/4885MDM4 2276/4885TP53 538/4885 |
| US-20220175875-A1 | METHODS OF TREATING CANCER BY TARGETING TUMOR-ASSOCIATED MACROPHAGES | FOLR1, FOLR2, FOLH1 | CASP3 1184/4885MDM4 1271/4885TP53 179/4885 |
| US-20220135594-A1 | METHODS OF SYNTHESIS AND INTERMEDIATES | PRTN3, NPR3, QPCTL | CASP3 188/4885MDM4 1434/4885TP53 1510/4885 |
| US-12576158-B2 | Antibody drug conjugates with cleavable linkers | PTMS, C3AR1, ANPEP | CASP3 168/4885MDM4 3831/4885TP53 394/4885 |
| US-20220112158-A1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDES AND PROTEIN CONJUGATES THEREOF | NR1H4, NR1H3, OGFR | CASP3 3771/4885MDM4 4813/4885TP53 3885/4885 |
| US-12497460-B2 | Anti-MSR1 antibodies and methods of use thereof | CD47, MSR1, LDLR | CASP3 3644/4885MDM4 3302/4885TP53 3840/4885 |
| US-20220080052-A1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDE DERIVATIVES AND PROTEIN CONJUGATES THEREOF FOR USE AS LXR AGONISTS | NR1H3, NR1H2, NR1H4 | CASP3 3522/4885MDM4 4665/4885TP53 4251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.